Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 11;27(3):210-219.
doi: 10.1093/oncolo/oyab038.

Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review

Damie J Juat  1 , Stephanie J Hachey  2 , John Billimek  2 , Michael P Del Rosario  3   4 , Edward L Nelson  1   3   4 , Christopher C W Hughes  1   5 , Jason A Zell  3   4
Affiliations

Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review

Damie J Juat et al. Oncologist. .

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the US. For the vast majority of patients with advanced CRC (ie, for those in whom metastatic tumors are unresectable), treatment is palliative and typically involves chemotherapy, biologic therapy, and/or immune checkpoint inhibition. In recent years, the use of adoptive T-cell therapy (ACT), leveraging the body's own immune system to recognize and target cancer, has become increasingly popular. Unfortunately, while ACT has been successful in the treatment of hematological malignancies, it is less efficacious in advanced CRC due in part to a lack of productive immune infiltrate. This systematic review was conducted to summarize the current data for the efficacy and safety of ACT in advanced CRC. We report that ACT is well tolerated in patients with advanced CRC. Favorable survival estimates among patients with advanced CRC receiving ACT demonstrate promise for this novel treatment paradigm. However, additional stage I/II clinical trials are needed to establish the efficacy and safety of ACT in patients with CRC.

Keywords: adoptive T-cell therapy; colorectal cancer; immunotherapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA flow diagram. Fifteen studies were included in this review.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. Colorectal (Colon) Cancer; 2020. Accessed February 20, 2020. https://www.cdc.gov/cancer/colorectal/basic_info/index.htm
    1. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197. - PMC - PubMed
    1. Zhang FF, Cudhea F, Shan Z, et al. Preventable Cancer burden associated with poor diet in the United States. JNCI Cancer Spectr 2019;3(2):pkz034. - PMC - PubMed
    1. National Comprehensive Cancer Network. Colon Cancer (Version 2.2021). Accessed June 6, 2021. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
    1. Kanat O, Ertas H. Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. World J Clin Oncol. 2019;10(2):52-61. - PMC - PubMed

Publication types

MeSH terms